---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-127874"
form_type: "8-K"
ticker: "ABT"
cik: "0000001800"
company_name: "ABBOTT LABORATORIES"
filed_at: "2021-10-20T23:59:59+00:00"
generated_at: "2026-06-28T19:42:53.051537+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Abbott Q3 sales $10.9B (+23.4%); adj. EPS $1.40 (+42.9%); raises FY guidance

## Summary
- GAAP diluted EPS $1.17; adjusted diluted EPS $1.40, up 42.9% vs 3Q20.
- Global COVID-19 testing sales $1.9B; total organic sales growth 22.4%.
- Full-year 2021 GAAP EPS guidance raised to $3.55-$3.65; adjusted $5.00-$5.10.
- Board declared $0.45 quarterly dividend (payable Nov. 15, 2021); 49th consecutive annual increase.
- Acquired Walk Vascular; received FDA approvals for Amplatzer Amulet, Portico TAVR, and Talisman PFO systems.

## SEC filing metadata
- accession: 0001104659-21-127874
- form_type: 8-K
- ticker: ABT
- cik: 0000001800
- company_name: ABBOTT LABORATORIES
- filed_at: 2021-10-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800/000110465921127874/0001104659-21-127874-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800/000110465921127874/tm2130546d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-127874
- JSON: https://secwatch.observer/filing/0001104659-21-127874.json
- Plain text: https://secwatch.observer/filing/0001104659-21-127874.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.